ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Ipsen and Merz Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

IpsenMerz Pharma
studies on the registry358172
open to participants now252
phase 3 studies under way165
reach primary completion within a year165
programswith a study of their own in two years91

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseIpsenMerz Pharma
Phase 1

Ipsen: 1 of its 9 programs at phase 1

  1. tovorafenibphase 1
11%
00%
Phase 244%00%
Phase 3

Ipsen: 4 of its 9 programs at phase 3

  1. corabotasephase 3
  2. elifibranorphase 3
  3. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3
  4. Palovarotenephase 3
44%
00%
Approved, new studies00%

Merz Pharma: 1 of its 1 programs at approved, new studies

  1. botulinum toxin type Aapproved, new study
100%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Ipsen3 readouts · 2 phase 3·

Ipsen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. corabotasephase 3 · Dec 15 · NCT07435428
  2. elifibranorphase 3 · Dec 17 · NCT06730061
·········

Ipsen, Oct ’27: 1 program whose next study reaches primary completion

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3 · Oct 15 · NCT04243499
Merz Pharma1 readouts · 1 phase 3····

Merz Pharma, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Mar 0 · NCT07018700
·······
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Ipsen

New programs 1

  • IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Merz Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionIpsenMerz Pharma
Migraine Disordersboth · compare here

Ipsen in Migraine Disorders: 1 program

  1. corabotasephase 3

Their studies: Ipsen’s studies of Migraine Disorders in search

Merz Pharma in Migraine Disorders: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: Merz Pharma’s studies of Migraine Disorders in search

Torticollisboth · compare here

Ipsen in Torticollis: 1 program

  1. corabotasephase 3

Their studies: Ipsen’s studies of Torticollis in search

Merz Pharma in Torticollis: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: Merz Pharma’s studies of Torticollis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Ipsen 4 of 9 · Merz Pharma 1 of 1 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.